Xeris Biopharma Holdings, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 38.01 million compared to USD 25.31 million a year ago. Net loss was USD 19.84 million compared to USD 26.19 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.19 a year ago.
For the six months, revenue was USD 71.2 million compared to USD 47.38 million a year ago. Net loss was USD 36.68 million compared to USD 59.9 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.44 a year ago.